Acute renal toxicity associated with suramin in the treatment of prostate cancer

William D. Figg; Michael R. Cooper; Alain Thibault; Donna Headlee; Jeffrey Humphrey; Raymond C. Bergan; Eddie Reed; Oliver Sartor

doi:10.1002/1097-0142(19940901)74:5<1612::AID-CNCR2820740519>3.0.CO;2-Q

Acute renal toxicity associated with suramin in the treatment of prostate cancer

William D. Figg^*, Michael R. Cooper, Alain Thibault, Donna Headlee, Jeffrey Humphrey, Raymond C. Bergan, Eddie Reed, Oliver Sartor

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

The use of suramin, a polysulfonated naphthylurea, in the treatment of advanced prostate cancer currently is being investigated. A 52‐year‐old man developed acute renal dysfunction after receiving nine doses of suramin. His suramin therapy was discontinued, but his serum creatinine level continued to rise to 10.8 mg/dl during the next 6 days. The patient was not rechallenged with suramin, and his renal function returned to baseline within the next 3 weeks. Future investigators of this drug should be aware of the possibility of such a reaction with parenteral administration.

Original language	English
Pages (from-to)	1612-1614
Number of pages	3
Journal	Cancer
Volume	74
Issue number	5
DOIs	https://doi.org/10.1002/1097-0142(19940901)74:5<1612::AID-CNCR2820740519>3.0.CO;2-Q
State	Published - 1 Sep 1994
Externally published	Yes

Keywords

acute renal failure
nephrotoxicity
prostate cancer
renal
suramin

Access to Document

10.1002/1097-0142(19940901)74:5<1612::AID-CNCR2820740519>3.0.CO;2-Q

Cite this

@article{1b132118f4ba46e5929065c78586b5b0,

title = "Acute renal toxicity associated with suramin in the treatment of prostate cancer",

abstract = "The use of suramin, a polysulfonated naphthylurea, in the treatment of advanced prostate cancer currently is being investigated. A 52‐year‐old man developed acute renal dysfunction after receiving nine doses of suramin. His suramin therapy was discontinued, but his serum creatinine level continued to rise to 10.8 mg/dl during the next 6 days. The patient was not rechallenged with suramin, and his renal function returned to baseline within the next 3 weeks. Future investigators of this drug should be aware of the possibility of such a reaction with parenteral administration.",

keywords = "acute renal failure, nephrotoxicity, prostate cancer, renal, suramin",

author = "Figg, {William D.} and Cooper, {Michael R.} and Alain Thibault and Donna Headlee and Jeffrey Humphrey and Bergan, {Raymond C.} and Eddie Reed and Oliver Sartor",

year = "1994",

month = sep,

day = "1",

doi = "10.1002/1097-0142(19940901)74:5<1612::AID-CNCR2820740519>3.0.CO;2-Q",

language = "English",

volume = "74",

pages = "1612--1614",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc",

number = "5",

}

TY - JOUR

T1 - Acute renal toxicity associated with suramin in the treatment of prostate cancer

AU - Figg, William D.

AU - Cooper, Michael R.

AU - Thibault, Alain

AU - Headlee, Donna

AU - Humphrey, Jeffrey

AU - Bergan, Raymond C.

AU - Reed, Eddie

AU - Sartor, Oliver

PY - 1994/9/1

Y1 - 1994/9/1

N2 - The use of suramin, a polysulfonated naphthylurea, in the treatment of advanced prostate cancer currently is being investigated. A 52‐year‐old man developed acute renal dysfunction after receiving nine doses of suramin. His suramin therapy was discontinued, but his serum creatinine level continued to rise to 10.8 mg/dl during the next 6 days. The patient was not rechallenged with suramin, and his renal function returned to baseline within the next 3 weeks. Future investigators of this drug should be aware of the possibility of such a reaction with parenteral administration.

AB - The use of suramin, a polysulfonated naphthylurea, in the treatment of advanced prostate cancer currently is being investigated. A 52‐year‐old man developed acute renal dysfunction after receiving nine doses of suramin. His suramin therapy was discontinued, but his serum creatinine level continued to rise to 10.8 mg/dl during the next 6 days. The patient was not rechallenged with suramin, and his renal function returned to baseline within the next 3 weeks. Future investigators of this drug should be aware of the possibility of such a reaction with parenteral administration.

KW - acute renal failure

KW - nephrotoxicity

KW - prostate cancer

KW - renal

KW - suramin

UR - http://www.scopus.com/inward/record.url?scp=0028068481&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19940901)74:5<1612::AID-CNCR2820740519>3.0.CO;2-Q

DO - 10.1002/1097-0142(19940901)74:5<1612::AID-CNCR2820740519>3.0.CO;2-Q

M3 - Article

C2 - 8062193

AN - SCOPUS:0028068481

SN - 0008-543X

VL - 74

SP - 1612

EP - 1614

JO - Cancer

JF - Cancer

IS - 5

ER -

Acute renal toxicity associated with suramin in the treatment of prostate cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this